{"id":33359,"date":"2021-06-08T06:31:00","date_gmt":"2021-06-07T23:31:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2021060806310033359"},"modified":"2021-06-08T21:37:45","modified_gmt":"2021-06-08T13:37:45","slug":"%e3%80%90%e7%9b%b4%e5%87%bb2021-asco%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%8f%a3%e5%a4%b4%e6%8a%a5%e5%91%8abcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e6%9c%80%e6%96%b0%e4%b8%b4%e5%ba%8a","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2021060806310033359","title":{"rendered":"\u3010\u76f4\u51fb2021 ASCO\u3011\u4e9a\u76db\u533b\u836f\u53e3\u5934\u62a5\u544aBcl-2\u6291\u5236\u5242APG-2575\u6700\u65b0\u4e34\u5e8a\u6570\u636e\uff0c\u6cbb\u7597\u590d\u53d1\u96be\u6cbbCLL\/SLL\u7684\u521d\u6b65\u7597\u6548\u548c\u5b89\u5168\u6027\u6f5c\u529b\u7a81\u51fa"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1419966\/logo_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><p>\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022021\u5e746\u67088\u65e5 \/\u7f8e\u901a\u793e\/ &#8212;&nbsp;\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u5904\u4e8e\u4e34\u5e8a\u9636\u6bb5\u7684\u7814\u53d1\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c&nbsp;\u516c\u53f8\u5df2\u5728\u7b2c57\u5c4a\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\uff08ASCO\uff09\u5e74\u4f1a\u4e0a\uff0c\u4ee5\u53e3\u5934\u62a5\u544a\u5f62\u5f0f\u516c\u5e03\u4e86Bcl-2\u6291\u5236\u5242lisaftoclax\uff08APG-2575\uff09\u5728\u590d\u53d1\/\u96be\u6cbb\u6027\uff08R\/R\uff09\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624(CLL\/SLL)\u548c\u5176\u4ed6\u8840\u6db2\u6076\u6027\u80bf\u7624\u60a3\u8005\u7684\u9996\u6b21\u4eba\u4f53\u8bd5\u9a8c\u6700\u65b0\u6570\u636e\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p>\u4f5c\u4e3a\u65e5\u76ca\u6d3b\u8dc3\u5728\u56fd\u9645\u5b66\u672f\u821e\u53f0\u4e0a\u7684\u201c\u4e2d\u56fd\u58f0\u97f3\u201c\uff0c&nbsp;\u4e9a\u76db\u533b\u836f\u5df2\u8fde\u7eed\u7b2c\u56db\u5e74\u4eae\u76f8ASCO\u5e74\u4f1a\u3002\u4eca\u5e74\uff0c\u4e9a\u76db\u533b\u836f\u5171\u6709\u56db\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009ASCO \u5e74\u4f1a\u5c55\u793a\u53ca\u62a5\u544a\uff0c\u5176\u4e2d2\u9879\u53e3\u5934\u62a5\u544a\u7684\u7814\u7a76\u6570\u636e\u4ee4\u4eba\u77a9\u76ee\u3002APG-2575\u7684\u6700\u65b0\u4e34\u5e8a\u6570\u636e\u521d\u6b65\u8868\u73b0\u51fa\u826f\u597d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u5176\u6cbb\u7597R\/R CLL\/SLL\u60a3\u8005\u7684\u5ba2\u89c2\u7f13\u89e3\u7387\uff08ORR\uff09\u8fbe80.0%\uff0c\u4e14\u8010\u53d7\u826f\u597d\uff0c\u4e0d\u826f\u4e8b\u4ef6\u53ef\u63a7\uff0c\u5728\u6700\u9ad8\u5242\u91cf1200mg\u4ecd\u672a\u89c2\u5bdf\u5230\u5242\u91cf\u9650\u5236\u6bd2\u6027\uff08DLT\uff09\uff0c\u4ecd\u672a\u8fbe\u5230\u6700\u5927\u8010\u53d7\u91cf\uff08MTD\uff09\uff0c\u65e0\u4e34\u5e8a\u6216\u5b9e\u9a8c\u5ba4\u80bf\u7624\u6eb6\u89e3\u7efc\u5408\u5f81(TLS)\u62a5\u544a\u3002<\/p>\n<p>\u7f8e\u56fd\u6885\u5965\u533b\u5b66\u79d1\u5b66\u7814\u7a76\u9662\uff08Mayo Clinic\uff09\u533b\u5b66\u6559\u6388\u3001\u8be5\u9879\u4e34\u5e8a\u7814\u7a76\u7684\u5168\u7403\u4e3b\u8981\u7814\u7a76\u8005Asher Chanan-Khan\u535a\u58eb\u8868\u793a\uff1a\u201cAPG-2575\u662f\u4e00\u79cd\u6709\u6548\u7684\u9009\u62e9\u6027Bcl-2\u6291\u5236\u5242\uff0c\u80fd\u8bf1\u5bfc\u7ec6\u80de\u51cb\u4ea1\uff0c\u6291\u5236\u7ec6\u80de\u751f\u957f\u3002\u5728\u7f8e\u56fd\u53ca\u6fb3\u5927\u5229\u4e9a\u7684\u9996\u6b21\u4eba\u4f53\u7814\u7a76\u4e2d\uff0cAPG-2575\u521d\u6b65\u663e\u793a\u51fa\u5bf9R\/R CLL\/SLL\u60a3\u8005\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u6781\u5177\u6f5c\u529b\u7684\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u5e76\u5bf9\u5176\u4ed6\u51e0\u79cd\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u4e5f\u6709\u6f5c\u5728\u7684\u75be\u75c5\u63a7\u5236\u4f5c\u7528\u3002\u57fa\u4e8e\u8fd9\u9879I\u671f\u4e34\u5e8a\u7814\u7a76\u7684\u7ed3\u679c\uff0c\u6211\u4eec\u671f\u5f85\u8fdb\u4e00\u6b65\u8bc4\u4f30APG-2575\u5728\u5176\u4ed6\u8840\u6db2\u80bf\u7624\u6216\u5b9e\u4f53\u7624\u4e2d\u7684\u6297\u80bf\u7624\u6d3b\u6027\u3002\u201d<\/p>\n<p>&nbsp;\u201cAPG-2575\u521d\u6b65\u5728R\/R CLL\/SLL\u60a3\u8005\u4e2d\u663e\u793a\u4e8680%\u7684\u5ba2\u89c2\u7f13\u89e3\u7387\uff0c\u4ee5\u53ca\u826f\u597d\u7684\u5b89\u5168\u6027\uff0c\u5373\u4f7f\u6bcf\u65e5\u9012\u589e\u5242\u91cf\uff0c\u4ecd\u672a\u89c2\u5bdf\u5230\u80bf\u7624\u6eb6\u89e3\u7efc\u5408\u5f81\u3002\u8be5\u7ed3\u679c\u975e\u5e38\u4ee4\u4eba\u632f\u594b\uff0c\u5e76\u518d\u4e00\u6b21\u5c55\u73b0\u4e86APG-2575\u7684&nbsp;\u201c\u540c\u7c7b\u6700\u4f73&nbsp;\u201c\u6f5c\u529b\u3002\u201d \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u8868\u793a\uff1a\u201c\u4eca\u5e74\uff0c\u6211\u4eec\u5728ASCO\u5e74\u4f1a\u4e0a\u8fdb\u884c\u4e86\u5305\u62ecAPG-2575\u5728\u5185\u7684\u4e24\u9879\u53e3\u5934\u62a5\u544a\u548c\u4e24\u9879\u58c1\u62a5\u5c55\u793a\u3002\u5bf9\u6b64\u6211\u611f\u5230\u975e\u5e38\u81ea\u8c6a\uff0c\u56e0\u4e3a\u8fd9\u662f\u4e9a\u76db\u533b\u836f\u5168\u7403\u521b\u65b0\u80fd\u529b\u7684\u4f53\u73b0\u3002&nbsp;\u672a\u6765\uff0c\u6211\u4eec\u5c06\u7ee7\u7eed\u79c9\u6301\u521d\u5fc3\uff0c\u575a\u5b88\u2018\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u2018\u8fd9\u4e00\u4f7f\u547d\uff0c\u52a0\u5feb\u4e34\u5e8a\u5f00\u53d1\uff0c\u8ba9\u5b89\u5168\u6709\u6548\u7684\u836f\u7269\u5c3d\u5feb\u4e0a\u5e02\uff0c\u65e9\u65e5\u60e0\u53ca\u60a3\u8005\u3002\u201d<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u57282021 ASCO\u5e74\u4f1a\u4e0a\u5c55\u793a\u7684\u4e34\u5e8a\u7814\u7a76\u6982\u89c8\uff1a<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"1\" class=\"prntblns\">\n<tbody>\n<tr>\n<td class=\"prnsbts prnrbrs prnvam prnsbbs prntac prnpl6 prnsbls prnpr6\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>\u4ea7\u54c1<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>\u6458\u8981<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>\u7f16\u53f7<\/b><\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>\u5f62\u5f0f<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Lisaftoclax<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">(APG-2575)<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">First-in-human study of lisaftoclax (APG-2575), a novel <\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">Bcl-2 inhibitor (Bcl-2i), in patients (pts) with relapsed\/refractory (R\/R) CLL <\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">and other hematologic malignancies (HMs)<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">\u65b0\u578bBcl-2\u6291\u5236\u5242APG-2575\u6cbb\u7597R\/R CLL\u53ca\u5176\u4ed6HMs\u60a3\u8005\u7684\u9996\u6b21\u4eba\u4f53\u8bd5\u9a8c<\/span><\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">7502<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen6\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">\u53e3\u5934<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">\u62a5\u544a<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td rowspan=\"2\" class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Alrizomadlin<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">(APG-115)<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, <\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">&nbsp;(pts) with unresectable or metastatic melanoma or advanced solid tumors that <\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">have failed immuno-oncologic (I-O) drugs<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">APG-115\u8054\u5408\u5e15\u535a\u5229\u73e0\u5355\u6297\u5e94\u7528\u4e8e\u7ecf\u514d\u75ab\u80bf\u7624\u836f\u7269\u6cbb\u7597\u5931\u8d25\u7684\u4e0d\u53ef\u5207\u9664\/\u8f6c\u79fb\u6027<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">\u9ed1\u8272\u7d20\u7624\u6216\u665a\u671f\u5b9e\u4f53\u7624\u60a3\u8005\u7684II\u671f\u4e34\u5e8a\u7814\u7a76\u521d\u6b65\u7ed3\u679c<\/span><\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">2506<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen6\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">\u53e3\u5934<br \/>\u62a5\u544a<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap class=\"prnsbt1 prnrbrs prnvab prnsbbs prnpl6 prnsbl1 prnpr6\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Trial in progress: A phase I\/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), <\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">APG-115\u5355\u836f\u6216\u8054\u5408\u94c2\u7c7b\u5316\u7597\u6cbb\u7597p53\u91ce\u751f\u578b\u553e\u6db2\u817a\u764c\u60a3\u8005\u7684I\/II\u671f\u4e34\u5e8a\u7814\u7a76<\/span><\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">TPS6094<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen6\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">\u58c1\u62a5<br \/>\u5c55\u793a<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Pelcitoclax<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">(APG-1252)<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Trial in progress: A multicenter phase Ib\/II study of pelcitoclax (APG-1252) in combination with <\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">paclitaxel in patients with relapsed\/refractory small-cell lung cancer (R\/R SCLC)<\/span><span class=\"prnews_span\">APG-1252<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">\u8054\u5408\u7d2b\u6749\u9187\u6cbb\u7597\u590d\u53d1\/\u96be\u6cbb\u6027\u5c0f\u7ec6\u80de\u80ba\u764c\uff08R\/R SCLC\uff09\u7684\u591a\u4e2d\u5fc3Ib\/II\u671f\u4e34\u5e8a\u7814\u7a76<\/span><\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">TPS8589<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen6\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">\u58c1\u62a5<br \/>\u5c55\u793a<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p><b>APG-2575<\/b><b>\u5728\u6b64\u6b21<\/b><b>ASCO<\/b><b>\u5e74\u4f1a\u4e0a\u53e3\u5934\u62a5\u544a\u7684\u6838\u5fc3\u8981\u70b9\uff1a<\/b><\/p>\n<p>First-in-human study of lisaftoclax (APG-2575), a novel Bcl-2 inhibitor (Bcl-2i), in patients (pts) with relapsed\/refractory (R\/R) CLL and other hematologic malignancies (HMs)&nbsp;<\/p>\n<p>\u65b0\u578bBcl-2\u6291\u5236\u5242APG-2575\u6cbb\u7597R\/R CLL\u53ca\u5176\u4ed6HMs\u60a3\u8005\u7684\u9996\u6b21\u4eba\u4f53\u8bd5\u9a8c<\/p>\n<p><b>\u6458\u8981\u7f16\u53f7\uff1a#7502<\/b><\/p>\n<ul type=\"disc\">\n<li>\u8fd9\u9879\u9996\u6b21\u5728\u4eba\u4f53\u8fdb\u884c\u7684\u5168\u7403I\u671f\u4e34\u5e8a\u7814\u7a76\u8bc4\u4f30\u4e86APG-2575\u5728R\/R CLL\u548c\u5176\u4ed6HMs\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u3001\u836f\u4ee3\u52a8\u529b\u5b66\uff08PK\uff09\u3001\u836f\u6548\u52a8\u529b\u5b66\uff08PD\uff09\u3001\u7597\u6548\u548c\u6700\u5927\u8010\u53d7\u91cf\uff08MTD\uff09\/II\u671f\u7814\u7a76\u63a8\u8350\u5242\u91cf\uff08RP2D\uff09\u3002APG-2575\u6bcf\u65e5\u53e3\u670d\u4e00\u6b21\uff0c28\u5929\u4e3a\u4e00\u4e2a\u5468\u671f\u3002CLL\u60a3\u8005\u6216\u80bf\u7624\u6eb6\u89e3\u7efc\u5408\u5f81(TLS)\u4e2d\/\u9ad8\u98ce\u9669\u60a3\u8005\u901a\u8fc7\u6bcf\u65e5\u5242\u91cf\u9012\u589e\u8fbe\u5230\u6307\u5b9a\u5242\u91cf\u3002 <\/li>\n<li>\u622a\u81f32021\u5e744\u670815\u65e5\uff0c36\u4f8b\u60a3\u8005\u88ab\u7eb3\u5165\u7814\u7a76\uff0c\u63a5\u53d7APG-2575 20-1200mg\u6cbb\u7597\uff0c\u4ed6\u4eec\u7684\u65e2\u5f80\u4e2d\u4f4d\u6cbb\u7597\u7ebf\u6570\uff08\u8303\u56f4\uff09\u4e3a2\uff081-13\uff09\uff0c\u88ab\u8bca\u65ad\u4e3aR\/R CLL\/SLL\uff08n=15\uff09\u3001\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\uff08n=6\uff09\u3001\u6ee4\u6ce1\u6027\u6dcb\u5df4\u7624\uff08FL\uff09\uff08n=5\uff09\u3001\u534e\u6c0f\u5de8\u7403\u86cb\u767d\u8840\u75c7\uff08WM\uff09\uff08n=5\uff09\uff0c\u4ee5\u53ca\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u3001\u5957\u7ec6\u80de\u6dcb\u5df4\u7624\uff08MCL\uff09\u3001\u5f25\u6f2b\u5927B\u7ec6\u80de\u6dcb\u5df4\u7624\uff08DLBCL\uff09\u3001\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\uff08MDS\uff09\u6216\u6bdb\u7ec6\u80de\u767d\u8840\u75c5\uff08HCL\uff1b\u5206\u522bn=1\uff09\u3002\u8fd9\u4e9b\u60a3\u8005\u63a5\u53d7\u4e86\u4e2d\u4f4d\uff08\u8303\u56f4\uff096\uff081-24\uff09\u4e2a\u5468\u671f\u7684APG-2575\u6cbb\u7597\u3002 <\/li>\n<li>APG-2575\u8010\u53d7\u6027\u826f\u597d\uff0c\u4e0d\u826f\u4e8b\u4ef6\u53ef\u63a7\u3002\u5728\u6700\u9ad8\u5242\u91cf1200mg\u4ecd\u672a\u89c2\u5bdf\u5230\u5242\u91cf\u9650\u5236\u6bd2\u6027\uff08DLT\uff09\uff0c\u672a\u8fbe\u5230MTD\uff0c\u65e0\u4e34\u5e8a\u6216\u5b9e\u9a8c\u5ba4TLS\u62a5\u544a\u3002\u5728\u88ab\u89c2\u5bdf\u5230\u7684\u4efb\u4f55\u7ea7\u522b\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\uff08TRAEs\uff09\u4e2d\uff0c\u53d1\u751f\u7387\u5927\u4e8e10%\u7684\u8840\u6db2\u5b66TRAEs\u5305\u62ec\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u548c\u8d2b\u8840\uff0c\u975e\u8840\u6db2\u5b66TRAEs\u5305\u62ec\u75b2\u4e4f\u3001\u8179\u6cfb\u3001\u4fbf\u79d8\u548c\u6076\u5fc3\u3002 <\/li>\n<li>15\u4f8b\u53ef\u8bc4\u4f30\u7684R\/R CLL\/SLL\u60a3\u8005\u4e2d\uff0c7\u4f8b\uff0846.7%\uff09\u4e3aRai\u5206\u7c7b\u75c5\u671f \u2162-\u2163\u671f\uff0c7\u4f8b\uff0846.7%\uff09\u4e3a\u56fd\u9645\u9884\u540e\u6307\u6570\uff08IPI\uff09\u9ad8\u5371-\u6781\u9ad8\u5371\u3002\u4e2d\u4f4d\uff08\u8303\u56f4\uff09\u6cbb\u75979\uff085-24\uff09\u4e2a\u5468\u671f\uff0c12\u4f8b\u60a3\u8005\u83b7\u5f97\u90e8\u5206\u7f13\u89e3\uff08PR\uff09\uff0cORR\u4e3a80.0%\uff0c\u4e2d\u4f4d\uff08\u8303\u56f4\uff09\u53cd\u5e94\u65f6\u95f4\u4e3a2\uff082-8\uff09\u4e2a\u6cbb\u7597\u5468\u671f\u3002 <\/li>\n<li>21\u4f8bR\/R\u975e CLL\/SLL\u60a3\u8005\u7684\u4e2d\u4f4d\uff08\u8303\u56f4\uff09\u65e2\u5f80\u6cbb\u7597\u7ebf\u6570\u4e3a3\uff081-13\uff09\uff0c\u5176\u4e2d\u53ef\u8bc4\u4f30\u60a3\u800520\u4f8b\u30021\u4f8b\u4f34\u6709t(11;14)\u7a81\u53d8\u7684MM\u60a3\u8005\u5728\u6cbb\u75972\u4e2a\u5468\u671f\u540e\u83b7\u5f97\u8f7b\u5fae\u7f13\u89e3\uff08MR\uff09\u3002\u517110\u4f8b\uff0850%\uff09\u60a3\u8005\u8fbe\u5230\u75be\u75c5\u7a33\u5b9a\uff08SD\uff09\u6216\u66f4\u6df1\u5ea6\u7684\u7f13\u89e3\u3002 <\/li>\n<li>\u521d\u6b65PK\u7ed3\u679c\u663e\u793a\uff0cAPG-2575\u7684\u66b4\u9732\u91cf\u4ece20mg\u52301200mg\u9010\u6e10\u589e\u52a0\uff08\u5e73\u5747\u534a\u8870\u671f\uff1a4-5\u5c0f\u65f6\uff09\u3002\u5728BH3\u8868\u8fbe\u8c31\u4e0a\uff0cAPG-2575\u8fc5\u901f\u89e6\u53d1CLL\/SLL\u60a3\u8005\u6837\u672c\u4e2dBCL-2\u590d\u5408\u7269\u7684\u53d8\u5316\uff0c\u8fd9\u4e0e\u4e34\u5e8a\u4e0a\u6dcb\u5df4\u7ec6\u80de\u7edd\u5bf9\u8ba1\u6570\uff08ALC\uff09\u7684\u5feb\u901f\u964d\u4f4e\u8868\u73b0\u4e00\u81f4\u3002 <\/li>\n<li>\u7ed3\u8bba\uff1a\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u6570\u636e\u8868\u660e\uff0cBcl-2\u6291\u5236\u5242APG-2575\u4e3aR\/R CLL\/SLL\u60a3\u8005\u548c\u5176\u4ed6HMs\u60a3\u8005\u63d0\u4f9b\u4e86\u4e00\u79cd\u5353\u6709\u6f5c\u529b\u7684\u66ff\u4ee3\u6cbb\u7597\u65b9\u6848\uff0c\u5176\u6bcf\u65e5\u5242\u91cf\u9012\u589e\u65b9\u6848\u5bf9\u60a3\u8005\u66f4\u53cb\u597d\u3002<\/li>\n<\/ul>\n<p>\u76f8\u5173\u94fe\u63a5 :<\/p>\n<blockquote class=\"wp-embedded-content\" data-secret=\"2VpXvImgpA\"><p><a href=\"https:\/\/www.ascentagepharma.com\/\">A Leader in the Discovery and Development of Small Molecules that Disrupt Protein-Protein Interactions<\/a><\/p><\/blockquote>\n<p><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; clip: rect(1px, 1px, 1px, 1px);\" title=\"&#8220;A Leader in the Discovery and Development of Small Molecules that Disrupt Protein-Protein Interactions&#8221; &#8212; Ascentage Pharma\" src=\"https:\/\/www.ascentagepharma.com\/embed\/#?secret=2VpXvImgpA\" data-secret=\"2VpXvImgpA\" width=\"600\" height=\"338\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022021\u5e746\u67088\u65e5 \/\u7f8e\u901a\u793e\/ &#8212;&nbsp;\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u5904\u4e8e\u4e34\u5e8a\u9636\u6bb5\u7684\u7814\u53d1\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c&nbsp;\u516c\u53f8\u5df2\u5728\u7b2c57\u5c4a\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\uff08ASCO\uff09\u5e74\u4f1a\u4e0a\uff0c\u4ee5\u53e3\u5934\u62a5\u544a\u5f62\u5f0f\u516c\u5e03\u4e86Bcl-2\u6291\u5236\u5242lisaftoclax\uff08APG-2575\uff09\u5728\u590d\u53d1\/\u96be\u6cbb\u6027\uff08R\/R\uff09\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624(CLL\/SLL)\u548c\u5176\u4ed6\u8840\u6db2\u6076\u6027\u80bf\u7624\u60a3\u8005\u7684\u9996\u6b21\u4eba\u4f53\u8bd5\u9a8c\u6700\u65b0\u6570\u636e\u3002 \u4f5c\u4e3a\u65e5\u76ca\u6d3b\u8dc3\u5728\u56fd\u9645\u5b66\u672f\u821e\u53f0\u4e0a\u7684\u201c\u4e2d\u56fd\u58f0\u97f3\u201c\uff0c&nbsp;\u4e9a\u76db\u533b\u836f\u5df2\u8fde\u7eed\u7b2c\u56db\u5e74\u4eae\u76f8ASCO\u5e74\u4f1a\u3002\u4eca\u5e74\uff0c\u4e9a\u76db\u533b\u836f\u5171\u6709\u56db\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009ASCO \u5e74\u4f1a\u5c55\u793a\u53ca\u62a5\u544a\uff0c\u5176\u4e2d2\u9879\u53e3\u5934\u62a5\u544a\u7684\u7814\u7a76\u6570\u636e\u4ee4\u4eba\u77a9\u76ee\u3002APG-2575\u7684\u6700\u65b0\u4e34\u5e8a\u6570\u636e\u521d\u6b65\u8868\u73b0\u51fa\u826f\u597d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u5176\u6cbb\u7597R\/R CLL\/SLL\u60a3\u8005\u7684\u5ba2\u89c2\u7f13\u89e3\u7387\uff08ORR\uff09\u8fbe80.0%\uff0c\u4e14\u8010\u53d7\u826f\u597d\uff0c\u4e0d\u826f\u4e8b\u4ef6\u53ef\u63a7\uff0c\u5728\u6700\u9ad8\u5242\u91cf1200mg\u4ecd\u672a\u89c2\u5bdf\u5230\u5242\u91cf\u9650\u5236\u6bd2\u6027\uff08DLT\uff09\uff0c\u4ecd\u672a\u8fbe\u5230\u6700\u5927\u8010\u53d7\u91cf\uff08MTD\uff09\uff0c\u65e0\u4e34\u5e8a\u6216\u5b9e\u9a8c\u5ba4\u80bf\u7624\u6eb6\u89e3\u7efc\u5408\u5f81(TLS)\u62a5\u544a\u3002 \u7f8e\u56fd\u6885\u5965\u533b\u5b66\u79d1\u5b66\u7814\u7a76\u9662\uff08Mayo Clinic\uff09\u533b\u5b66\u6559\u6388\u3001\u8be5\u9879\u4e34\u5e8a\u7814\u7a76\u7684\u5168\u7403\u4e3b\u8981\u7814\u7a76\u8005Asher Chanan-Khan\u535a\u58eb\u8868\u793a\uff1a\u201cAPG-2575\u662f\u4e00\u79cd\u6709\u6548\u7684\u9009\u62e9\u6027Bcl-2\u6291\u5236\u5242\uff0c\u80fd\u8bf1\u5bfc\u7ec6\u80de\u51cb\u4ea1\uff0c\u6291\u5236\u7ec6\u80de\u751f\u957f\u3002\u5728\u7f8e\u56fd\u53ca\u6fb3\u5927\u5229\u4e9a\u7684\u9996\u6b21\u4eba\u4f53\u7814\u7a76\u4e2d\uff0cAPG-2575\u521d\u6b65\u663e\u793a\u51fa\u5bf9R\/R CLL\/SLL\u60a3\u8005\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u6781\u5177\u6f5c\u529b\u7684\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u5e76\u5bf9\u5176\u4ed6\u51e0\u79cd\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u4e5f\u6709\u6f5c\u5728\u7684\u75be\u75c5\u63a7\u5236\u4f5c\u7528\u3002\u57fa\u4e8e\u8fd9\u9879I\u671f\u4e34\u5e8a\u7814\u7a76\u7684\u7ed3\u679c\uff0c\u6211\u4eec\u671f\u5f85\u8fdb\u4e00\u6b65\u8bc4\u4f30APG-2575\u5728\u5176\u4ed6\u8840\u6db2\u80bf\u7624\u6216\u5b9e\u4f53\u7624\u4e2d\u7684\u6297\u80bf\u7624\u6d3b\u6027\u3002\u201d &nbsp;\u201cAPG-2575\u521d\u6b65\u5728R\/R CLL\/SLL\u60a3\u8005\u4e2d\u663e\u793a\u4e8680%\u7684\u5ba2\u89c2\u7f13\u89e3\u7387\uff0c\u4ee5\u53ca\u826f\u597d\u7684\u5b89\u5168\u6027\uff0c\u5373\u4f7f\u6bcf\u65e5\u9012\u589e\u5242\u91cf\uff0c\u4ecd\u672a\u89c2\u5bdf\u5230\u80bf\u7624\u6eb6\u89e3\u7efc\u5408\u5f81\u3002\u8be5\u7ed3\u679c\u975e\u5e38\u4ee4\u4eba\u632f\u594b\uff0c\u5e76\u518d\u4e00\u6b21\u5c55\u73b0\u4e86APG-2575\u7684&nbsp;\u201c\u540c\u7c7b\u6700\u4f73&nbsp;\u201c\u6f5c\u529b\u3002\u201d \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u8868\u793a\uff1a\u201c\u4eca\u5e74\uff0c\u6211\u4eec\u5728ASCO\u5e74\u4f1a\u4e0a\u8fdb\u884c\u4e86\u5305\u62ecAPG-2575\u5728\u5185\u7684\u4e24\u9879\u53e3\u5934\u62a5\u544a\u548c\u4e24\u9879\u58c1\u62a5\u5c55\u793a\u3002\u5bf9\u6b64\u6211\u611f\u5230\u975e\u5e38\u81ea\u8c6a\uff0c\u56e0\u4e3a\u8fd9\u662f\u4e9a\u76db\u533b\u836f\u5168\u7403\u521b\u65b0\u80fd\u529b\u7684\u4f53\u73b0\u3002&nbsp;\u672a\u6765\uff0c\u6211\u4eec\u5c06\u7ee7\u7eed\u79c9\u6301\u521d\u5fc3\uff0c\u575a\u5b88\u2018\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u2018\u8fd9\u4e00\u4f7f\u547d\uff0c\u52a0\u5feb\u4e34\u5e8a\u5f00\u53d1\uff0c\u8ba9\u5b89\u5168\u6709\u6548\u7684\u836f\u7269\u5c3d\u5feb\u4e0a\u5e02\uff0c\u65e9\u65e5\u60e0\u53ca\u60a3\u8005\u3002\u201d \u4e9a\u76db\u533b\u836f\u57282021 ASCO\u5e74\u4f1a\u4e0a\u5c55\u793a\u7684\u4e34\u5e8a\u7814\u7a76\u6982\u89c8\uff1a \u4ea7\u54c1 \u6458\u8981 \u7f16\u53f7 \u5f62\u5f0f Lisaftoclax (APG-2575) First-in-human study of lisaftoclax (APG-2575), a novel Bcl-2 inhibitor (Bcl-2i), in patients (pts) with relapsed\/refractory (R\/R) CLL and other hematologic malignancies (HMs) \u65b0\u578bBcl-2\u6291\u5236\u5242APG-2575\u6cbb\u7597R\/R CLL\u53ca\u5176\u4ed6HMs\u60a3\u8005\u7684\u9996\u6b21\u4eba\u4f53\u8bd5\u9a8c 7502 \u53e3\u5934 \u62a5\u544a Alrizomadlin (APG-115) Preliminary results of a phase&hellip; <a class=\"read-more\" href=\"https:\/\/www.xinwengao.com\/cn\/pr\/2021060806310033359\">Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":8278,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-33359","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/33359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=33359"}],"version-history":[{"count":2,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/33359\/revisions"}],"predecessor-version":[{"id":33362,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/33359\/revisions\/33362"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/8278"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=33359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=33359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=33359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}